NewLink Genetics Corporation approved, subject to stockholder approval, a Certificate of Amendment to the company's Restated Certificate of Incorporation to increase the total number of authorized shares from 43,833,334 to 80,000,000 and to increase the total number of authorized shares of common stock from 38,833,334 to 75,000,000.

NewLink Genetics Corporation announced unaudited consolidated earnings results for the first quarter ended March 31, 2013. For the quarter, the company reported grant revenue was $0.302 million against $0.471 million a year ago. Loss from operations was $8.042 million against $4.817 million a year ago. Net loss attributable to NewLink was $7.934 million against $4.842 million a year ago. Basic and diluted loss per share was $0.33 against $0.23 a year ago.

NewLink Genetics Corporation announced that the company presented preclinical data for NLG919, a potent IDO (indoleamine-(2,3)-dioxygenase) pathway inhibitor, at the American Association for Cancer Research (AACR) 2013 annual meeting. These data demonstrate that NLG919 potently inhibits the IDO pathway in vitro and in cell based assays, is orally bioavailable and has a favorable pharmacologic and toxicity profile. NLG919 is the second pipeline candidate from NewLink's IDO Pathway Inhibitor technology platform to be announced. This platform has also produced indoximod (NLG8189 or D1-MT) which is currently in Phase 2 clinical trials for the treatment of prostate cancer and metastatic breast cancer. Furthermore, NLG919 and indoximod show remarkable synergistic T-cell activation and antitumor activity. In a poster presentation entitled "NLG919, a novel indoleamine-2,3-dioxygenase (IDO)-pathway inhibitor drug candidate for cancer therapy," NewLink scientists presented preclinical data to demonstrate NLG919's on target anti-tumor effects as well as favorable oral bioavailability, pharmacokinetic and pharmacodynamic profiles. The principal findings reported in the NLG919 study include: NLG919 potently inhibits the IDO pathway in vitro and in cell based assays. NLG919 potently blocks IDO-induced antigen-specific T-cell suppression and restores robust T-cell responses. NLG919 demonstrates single agent anti-tumor activity. NLG919 and indoximod show synergistic T-cell activation and antitumor activities. NLG919 is orally bioavailable and has a favorable pharmacokinetic and toxicity profile.